Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Handbook of Experimental Pharmacology|April 14, 2006
Hsp90 inhibitors in the clinicS Pacey, U Banerji, I Judson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsA Stewart, P Thavasu, J S de Bono, et al.
Clinical Pharmacology and Therapeutics|January 20, 2009
From darkness to light with biomarkers in early clinical trials of cancer drugsC P Carden, U Banerji, S B Kaye, et al.
Oncogene|August 30, 2000
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperoneP A Clarke, I Hostein, U Banerji, et al.
Breast (Edinburgh, Scotland)|March 24, 2007
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?Y S Yap, A Kendall, G Walsh, et al.
Lung Cancer (Amsterdam, Netherlands)|June 25, 2014
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell linesM Puglisi, P Thavasu, A Stewart, et al.
British Journal of Cancer|April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 15, 2000
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinomaJ I Geh, R Glynne-Jones, Q S Kwok, et al.
ESMO Open|February 22, 2024
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)N Lakhani, R Cosman, U Banerji, et al.
British Journal of Cancer|September 1, 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphomaA Naing, C Aghajanian, E Raymond, et al.
Pageof 3